BENEFITS OF BIOMARKER TESTING

- Can help you gather as much information as possible about a person’s lung cancer, ideally before starting treatment
- Help to determine whether a targeted drug therapy or a specific immunotherapy drug would be the best treatment option
- For biomarker-driven therapies that are not yet FDA-approved, clinical trials may be available and an appropriate option depending on the case

WHEN TO TEST

- Biomarker testing should be performed for all patients with metastatic lung cancer before initiating first line therapy
- Biomarker testing should be considered for select patients with stage I-III disease
- This area is rapidly changing and we recommend referring to NCCN guidelines for a specific guidance

FOR YOUR PATIENTS

- PD-L1
- EGFR
- ALK
- ROS1
- BRAF
- NTRK
- MET
- RET
- HER2
- KRAS

For SCLC, currently, biomarker testing is only being conducted for clinical trials.

DRIVER MUTATIONS/ BIOMARKERS

For NSCLC/ Lung Adenocarcinoma

- ACCC
- CancerCare
- CancerGRACE
- Family Reach
- Lung Cancer Research Foundation
- ALK Positive
- EGFR Cancer.org
- American Lung Association
- International Association for the Study of Lung Cancer (IASLC)

FROM A PATIENT

"My lung cancer biomarker test guided my treatment path. Learning my tumor was KRAS-positive allowed me to make the most informed treatment decisions for my lung cancer."

- Terri, Stage IIA non-small lung cancer survivor

FROM A CARE PROVIDER

When discussing new treatments based on biomarker testing, Dr. Jhanelle Gray from Moffitt Cancer Center says:

"We need to be careful when we use the words manage or managing. We're not managing the patient, we're managing the therapies, we're helping to manage the symptoms that patients experience. We also want to take time to slow down, look at what is happening in the room as you're talking, as the patient is talking to you. Language is something that is critically important."

Empowering Providers to Empower Patients (EPEP) is brought to you by Patient Empowerment Network. It is made possible through support from Amgen, Sanofi and generous donations from people like you.

© 2023 Patient Empowerment Network, a 501(c)(3) Public Charity

Sources: LUNGevity Foundation, Patient Empowerment Network, Cancer.net